REDUCTIL REDUCTIL BUTASLIM OBERID OBERID LIGHT LIGHT SIBESY SIBESY OBORID OBORID NOBESE NOBESE SLIMER SLIMER SLASH 3H SLASH 3H TRIM FAST TRIM FAST ACCENT ACCENT KALGRAY KALGRAY OBESIB OBESIB GETSET GETSET KALGARY MERIDA MERIDA XOBNOC RETRIM RETRIM SIBUTRA SIBUTRA SIBUTRA TRAI SIBURA SIBURA SLIMFIG

Dose: 10 mg
Single Dose: 10 (10)
Frequency: 24 hourly
Route: PO
Instructions: Initially, increased to 15mg if weight loss is

Sibutramine HCl is the derivative of Sibutramine. It is of Synthetic origin. . The Molecular Weight of Sibutramine is 279.80.

Sibutramine is contraindicated in conditions like Hyperthyroidism,Phaeochromocytoma,Prostatic hypertrophy,Congestive heart failure,Cerebrovascular disease,Coronary artery disease,Angle-closure glaucoma,Uncontrolled hypertension,Peripheral arterial occlusive disease,Psychotic illness,Thyrotoxicosis (adjunct),Infections due to senstive gram +ve and gram -ve bacteria.

The severe or irreversible adverse effects of Sibutramine, which give rise to further complications include Increased blood pressure, Seizures, Bleeding, Acute interstitial nephritis, Migraine.The symptomatic adverse reactions produced by Sibutramine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Diarrhea, Constipation, Insomnia, Dry mouth, Depression, Edema, Rhinitis, Dysmenorrhea.

Sibutramine is primarily indicated in conditions like Bleeding caused by uterine atony, Obesity.

Sibutramine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementDextromethorphanEphedrineErythromycinFentanyl (Citrate)KetoconazoleLithiumPentazocinePethidine (HCl)Phenylpropanolamine (HCl)Pseudoephedrine (HCl)SumatriptanVORICONAZOLEVoriconazole may increase the serum concentration of sibutramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Abnormal LFTs Increased Alkaline Phosphatase LevelsElevation in ALT or AST

Drug should not be given to Cardiac / Hypertensive Patients.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Caps Store in a well closed container, Between 15°C-30°C. Protect from Sunlight, Moisture and Heat.

Monitor blood pressure and pulse rate (every two weeks for first three months then monthly for three months then atleast every three months)---- discontinue if blood pressure exeeds 145/90 mmHg or if systolic or diastolic pressure raised by 10mmHg or if pulse rate raised by 10 beats per minute at two consecutive visits; sleep apnoea syndrome (increased risk of hypertension); epilepsy; hepatic impairment (avoid if severe); renal impairment (avoid if severe); monitor for pulmonary hypertension; family history of motor or vocal tics. DISCONTINUATION OF TREATMENT: Discontinue treatment if : weight loss after three months less than 5% of initial body weight; weight loss stabilises at less than 5% of initial body weight; individuals regain 3 kg or more after previous weight loss. In individuals with co-morbid conditions, treatment should be continued only if weight loss is associated with other clinical benefits.